You will receive treatment for rheumatoid arthritis using one of the following medications:

– Ravagalimab through subcutaneous injection (under the skin)

– Lutikizumab through subcutaneous injection

– A placebo (inactive substance) for comparison

You will continue taking your current methotrexate medication at the same dose throughout the study

Your response to the treatment will be monitored for 12 weeks

The doctor will measure your improvement using several methods:

– Checking if your joint symptoms have improved by 20%, 50%, or 70%

– Measuring your overall disease activity

– Testing your blood for signs of inflammation using a test called C-Reactive Protein (CRP)

Regular assessments will track changes in your condition throughout this period

Your disease activity will be measured using two different methods:

– Disease Activity Score-28 (DAS28): measures activity in 28 specific joints

– Clinical Disease Activity Index (CDAI): another way to measure how active your arthritis is

These measurements will help determine if you have achieved:

– Low disease activity

– Clinical remission (minimal to no active disease)

The entire study is expected to run from October 2025 to February 2027

Your participation will help evaluate how well these medications work for treating moderate to severe rheumatoid arthritis

Regular monitoring of your health and safety will continue throughout the study period